Neues zur Diagnostik und Therapie der Riesenzellarteriitis

Was ist neu?

Bildgebende Diagnostik Eine rein B-Bild-basierte Ultraschalldiagnostik kann die Akzeptanz und den breiten, zeitgerechten Einsatz des Ultraschalls in der Diagnostik der Riesenzellarteriitis befördern und so die Patientenversorgung verbessern. Der Kontrastmittelultraschall könnte einen Stellenwert in der bildgebenden Ad-hoc-Beurteilung der Vaskulitisaktivität bei Riesenzellarteriitis mit Beteiligung extrakranialer Arterien unter Therapie haben.

Therapie Mit dem Interleukin-6-Rezeptor-Antagonisten Tocilizumab steht eine effektive, explizit für die Riesenzellarteriitis zugelassene Therapie zur Verfügung.

Abstract

Giant cell arteritis (GCA) is the most common form of the primary large vessel vasculitides and typically occurs in individuals aged ≥ 50 years. This concise review article discusses current trends in the management of GCA, including important developments in sonographic assessment (B-mode sonography, contrast enhanced ultrasound) and medical treatment (biological treatment with the interleukin-6 receptor alpha inhibitor tocilizumab).

Schlüsselwörter

Riesenzellarteriitis - Ultraschall - Kompressionssonografie - Kontrastmittelsonografie - Interleukin-6 - Tocilizumab

Key words

giant cell arteritis - ultrasound - contrast-enhanced ultrasound - compression ultrasound - interleukin-6 - tocilizumab

• Literatur

• 1 Czihal M, Lottspeich C, Hoffmann U. Ultrasound imaging in the diagnosis of large vessel vasculitis. Vasa 2017; 46: 241-253
• 2 Diamantopoulos AP, Haugeberg G, Lindland A. et al. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis?. Rheumatology (Oxford) 2016; 55: 66-70
• 3 Patil P, Williams M, Maw WW. et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol 2015; 33: S-103-S-106
• 4 Luqmani R, Lee E, Singh S. et al. The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess 2016; 20: 1-238
• 5 Schäfer VS, Juche A, Ramiro S. et al. Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology (Oxford) 2017; 56: 1479-1483
• 6 Czihal M, Schröttle A, Baustel K. et al. B-mode sonography wall thickness assessment of the temporal and axillary arteries for the diagnosis of giant cell arteritis: a cohort study. Clin Exp Rheumatol 2017; 35: 128-133
• 7 Aschwanden M, Daikeler T, Kesten F. et al. Temporal artery compression sign – a novel ultrasound finding for the diagnosis of giant cell arteritis. Ultraschall Med 2013; 34: 47-50
• 8 Dejaco C, Ramiro S, Duftner C. et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. . 2018 Jan 22. [Epub ahead of print]
• 9 Germanò G, Macchioni P, Possemato N. et al. Contrast-Enhanced Ultrasound of the Carotid Artery in Patients With Large Vessel Vasculitis: Correlation With Positron Emission Tomography Findings. Arthritis Care Res (Hoboken) 2017; 69: 143-149
• 10 Restuccia G, Boiardi L, Cavazza A. et al. Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study. Medicine (Baltimore) 2016; 95: e3524
• 11 Wilson JC, Sarsour K, Collinson N. et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis. Semin Arthritis Rheum 2017; 46: 819-827
• 12 Liddle J, Bartlam R, Mallen CD. et al. What is the impact of giant cell arteritis on patients’ lives? A UK qualitative study. BMJ Open 2017; 7: e017073
• 13 Villiger PM, Adler S, Kuchen S. et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387: 1921-1927
• 14 Stone JH, Tuckwell K, Dimonaco S. et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 2017; 377: 317-328